- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07568951
Impact of Force Control of Hip Abductor Muscles in Healthy Adults and Individuals With Parkinson's Disease
Impact of Force Control of Hip Abductor Muscles on Postural Control in Middle-aged and Older Adults and Individuals With Parkinson's Disease
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Both aging and Parkinson's disease (PD) negatively affect postural control and increase the risk of falls, with frontal plane balance being particularly challenging for these populations. Previous studies have mainly focused on sagittal plane balance and have identified the important roles of ankle plantar flexors and knee extensors; however, the contribution of hip abductor muscles-key muscles for frontal plane stability-remains unclear, particularly in terms of their force production and control abilities. Therefore, this study aims to investigate hip abductor muscle force production and force control, and to examine whether these factors are associated with postural control, gait, and balance performance in individuals across different ages and those with PD. Healthy young, middle-aged, and older adults will be recruited from the community, and individuals with PD will be recruited from the Department of Neurology. Healthy participants must be in good health, able to walk independently, demonstrate normal cognitive function, and provide informed consent, while those with neurological, cardiovascular, musculoskeletal, or other conditions affecting motor performance will be excluded. For individuals with PD, inclusion criteria will be a clinical diagnosis of idiopathic PD, Hoehn and Yahr stages 1 to 3, stable anti-PD medication use, and the ability to follow instructions and walk at least 10 m. Exclusion criteria will include psychiatric, immune, integumentary, or musculoskeletal disorders, neurological conditions other than PD, lower extremity pain, uncontrolled cardiovascular disease, or inability to provide informed consent. All participants will undergo a one-time assessment, including maximal voluntary isometric contraction, force steadiness, postural control, and gait performance.
Surface electromyography will be used to assess neuromuscular function, postural control will be evaluated using a force plate under multiple standing conditions, and gait parameters will be measured at both comfortable and fast walking speeds. Statistical analyses will be conducted using ANOVA to examine group differences.
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Chu-Ling Yen
- Telefonnummer: 3059 886-3-2118800
- E-post: clyen@mail.cgu.edu.tw
Studieorter
-
-
-
Taoyuan, Taiwan
- Rekrytering
- Chang Gung Memorial Hospital
-
Kontakt:
- Chu-Ling Yen
- Telefonnummer: 3059 886-3-2118800
- E-post: clyen@mail.cgu.edu.tw
-
Taoyuan, Taiwan
- Rekrytering
- Chang Gung University
-
Kontakt:
- Chu-Ling Yen
- Telefonnummer: 3059 886-3-2118800
- E-post: clyen@mail.cgu.edu.tw
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Testmetod
Studera befolkning
Beskrivning
Healthy people
Inclusion Criteria:
- 20 to 39 years (young), 40 to 59 years (young), and 60-85 years (old)
- generally in good health
- able to walk 10 m independently
- able to follow all instructions
Exclusion Criteria:
- neurologic, psychiatric, immune, integumentary, and musculoskeletal diseases or disorders which might influence this study
- any pain over the lower extremities
- uncontrolled cardiovascular diseases
- unable to provide informed consent.
PD
Inclusion Criteria:
- clinical diagnosis of idiopathic PD
- Hoehn and Yahr stages 1 to 3
- stable anti-PD medications
- able to walk 10 m independently
- able to follow all instructions
Exclusion Criteria:
- psychiatric, immune, integumentary, and musculoskeletal diseases or disorders which might influence this study
- neurological conditions other than PD
- any pain over the lower extremities
- uncontrolled cardiovascular diseases
- unable to provide informed consent.
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Healthy people
General healthy adults
|
We compare the young, middle-aged, and old groups
We compare the healthy group and PD group.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Maximal force
Tidsram: Baseline
|
The maximal force of lower extremity muscles
|
Baseline
|
|
Rate of torque development
Tidsram: Baseline
|
The ability to rapidly generate muscle force
|
Baseline
|
|
Force steadiness
Tidsram: Baseline
|
The ability to maintain a constant force output during a submaximal contraction
|
Baseline
|
|
Walking speed
Tidsram: Baseline
|
The time taken by participants to walk a standardized distance
|
Baseline
|
|
Step Length
Tidsram: Baseline
|
The linear distance between the two ankles, typically expressed in centimeter(cm).
|
Baseline
|
|
Cadence
Tidsram: Baseline
|
The number of steps taken per minute (SPM)
|
Baseline
|
|
Single Support Time
Tidsram: Baseline
|
The duration within the gait cycle when only one foot is in contact with the ground, typically measured in seconds or as a percentage of the total gait cycle.
|
Baseline
|
|
Double Support Time
Tidsram: Baseline
|
The portion of the gait cycle where both feet are in contact with the ground, indicating the transition phase between steps, expressed as a percentage of the gait cycle or in seconds.
|
Baseline
|
|
Swing Time
Tidsram: Baseline
|
The portion of the gait cycle where the foot is not in contact with the ground, moving forward to the next step.
It is usually expressed as a percentage of the total gait cycle or in seconds.
|
Baseline
|
|
Timed Up-and-Go Test
Tidsram: Baseline
|
Tthe time an individual takes to stand up from a chair, walk 3 meters, turn around, walk back, and sit down.
|
Baseline
|
|
Four Square Step Test
Tidsram: Baseline
|
Participants will be required to perform four square step test by changing directions while stepping forward, sideway, and backward over a low obstacle as fast as possible.
|
Baseline
|
|
Center of Pressure (COP) Velocity in Balance Tasks
Tidsram: Baseline
|
The speed at which the COP moves, calculated over the duration of the balance task.
Higher velocities may reflect more dynamic balance adjustments or instability.
Unit:millimeter per second(mm/s)
|
Baseline
|
|
Center of Pressure (COP) Area in Balance Tasks
Tidsram: Baseline
|
The area covered by the COP trajectory during the balance task, providing an estimate of the sway envelope.
A larger area might indicate poorer balance control.
Unit:square millimeter(mm^2)
|
Baseline
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Chu-Ling Yen, Chang Gung University
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Synukleinopatier
- Hjärnsjukdomar
- Sjukdomar i centrala nervsystemet
- Sjukdomar i nervsystemet
- Neurodegenerativa sjukdomar
- Rörelsestörningar
- Parkinsons sjukdom
- Basala ganglia sjukdomar
- Parkinsons sjukdom
- Fysiologiska fenomen
- Beteendediscipliner och aktiviteter
- Psykologiska tester
- Tillväxt och utveckling
- Neuropsykologiska test
- Mental status och demensprov
- Åldrande
Andra studie-ID-nummer
- 202202289A3
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .